Table 2.

The importance of types of information for making decisions to use biosimilar products (n = 206).

Statement	Important/Extremely Important	Selected as Being in the Three Most Important Statements
Studies that provide clinical immunogenicity data for the biosimilar and reference product	97%	42%
Studies that directly compare clinical efficacy and safety between reference products and biosimilars	96%	68%
Studies that show pharmacokinetic similarities between reference products and biosimilars	96%	30%
Inclusion in international and Russian clinical practice guidelines and standards of treatment	95%	55%
Studies that show chemical/physical similarities between reference products and biosimilars	89%	24%
Studies that compare activity with in vitro functional assays between reference products and biosimilars	87%	21%
Acquisition cost differences	78%	31%
Colleague and expert opinion	78%	8%
Payer decisions and requirements	69%	21%

Data were extracted from question 10 of the questionnaire (see Survey Questionnaire 1).